Safety and Efficacy of PCSK9 Inhibitor Treatment in Heart Transplant Patients

被引：10
|
作者：
Di Nora, Concetta [1 ]
Sponga, Sandro [1 ]
Livi, Ugolino [1 ]
机构：
[1] Azienda Sanit Univ Integrata Udine, Dept Cardiothorac Sci, Udine, Italy
来源：
TRANSPLANTATION | 2019年 / 103卷 / 03期
关键词：
RISK;
D O I：
10.1097/TP.0000000000002520
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：E58 / E58
页数：1
相关论文
共 50 条
  • [41] Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan
    Kodera, Satoshi
    Morita, Hiroyuki
    Kiyosue, Arihiro
    Ando, Jiro
    Takura, Tomoyuki
    Komuro, Issei
    CIRCULATION JOURNAL, 2018, 82 (10) : 2602 - 2608
  • [42] Using Human 'Experiments of Nature' to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors
    Jerome, Rebecca N.
    Pulley, Jill M.
    Roden, Dan M.
    Shirey-Rice, Jana K.
    Bastarache, Lisa A.
    Bernard, Gordon R.
    Ekstrom, Leeland B.
    Lancaster, William J.
    Denny, Joshua C.
    DRUG SAFETY, 2018, 41 (03) : 303 - 311
  • [43] Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects
    Anderson, Jacqueline M.
    Cerda, Alvaro
    Hirata, Mario H.
    Rodrigues, Alice C.
    Dorea, Egidio L.
    Bernik, Marcia M. S.
    Bertolami, Marcelo C.
    Faludi, Andre A.
    Hirata, Rosario D. C.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2014, 8 (03) : 256 - 264
  • [44] Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy
    Navar, Ann Marie
    Taylor, Benjamin
    Mulder, Hillary
    Fievitz, Eugene
    Monda, Keri L.
    Fievitz, Anna
    Maya, Juan F.
    Lopez, J. Antonio G.
    Peterson, Eric D.
    JAMA CARDIOLOGY, 2017, 2 (11) : 1217 - 1225
  • [45] Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616
    Ballantyne, Christie M.
    Banka, Puja
    Mendez, Gustavo
    Garcia, Raymundo
    Rosenstock, Julio
    Rodgers, Anthony
    Mendizabal, Geraldine
    Mitchel, Yale
    Catapano, Alberico L.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (16) : 1553 - 1564
  • [46] Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study
    Xie, Weijia
    Li, Jiaxin
    Du, Hao
    Xia, Jian
    ARTHRITIS RESEARCH & THERAPY, 2023, 25 (01)
  • [47] Sex Differences Associated With Circulating PCSK9 in Patients Presenting With Acute Myocardial Infarction
    Zhang, Zhong
    Wei, Teng-Fei
    Zhao, Bei
    Yin, Zhao
    Shi, Quan-Xing
    Liu, Pei-Lin
    Liu, Li-Feng
    Liu, Li
    Zhao, Jing-Tao
    Mao, Shuai
    Rao, Meng-Meng
    Wang, Shou-Li
    Chen, Yun-Dai
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [48] Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation
    Pastori, Daniele
    Nocella, Cristina
    Farcomeni, Alessio
    Bartimoccia, Simona
    Santulli, Maria
    Vasaturo, Fortunata
    Carnevale, Roberto
    Menichelli, Danilo
    Violi, Francesco
    Pignatelli, Pasquale
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (12) : 1455 - 1462
  • [49] The effect of APOE, CETP, and PCSK9 polymorphisms on simvastatin response in Thai hypercholesterolemic patients
    Wanmasae, Smith
    Sirintronsopon, Wisant
    Porntadavity, Sureerut
    Jeenduang, Nutjaree
    CARDIOVASCULAR THERAPEUTICS, 2017, 35 (06)
  • [50] Eligibility for treatment with PCSK9 inhibitors among patients with stable coronary artery disease presumed to be on maximum hypolipidaemic therapy
    Rallidis, Loukianos S.
    Triantafyllis, Andreas S.
    HELLENIC JOURNAL OF CARDIOLOGY, 2018, 59 (05) : 293 - 295
12345